Evidence map›Paper›PMID 42638751›Full record

ArticleFrontiers in tuberculosis2024

Serum-derived host miR-423-5p and miR-378a-3p as molecular markers for severe tuberculosis: a promising prognostic tool for survival.

Joaquin Hurtado, María Buroni, Alvaro Giordano, Nicolas Nin, F Javier Hurtado, Juan Pablo Tosar, Carlos Robello, Gonzalo Greif

Abstract read
In one paragraph

Article in Frontiers in tuberculosis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joaquin HurtadoLaboratorio de Interacciones Hospedero-Patógeno, Institut Pasteur de Montevideo, Montevideo, Uruguay.
María BuroniUnidad de Cuidados Intensivos, Hospital Español Dr. "Juan J. Crottoggini", Administración de los Servicios de Salud del Estado (ASSE), Montevideo, Uruguay.
Alvaro GiordanoUnidad de Cuidados Intensivos, Hospital Español Dr. "Juan J. Crottoggini", Administración de los Servicios de Salud del Estado (ASSE), Montevideo, Uruguay.
Nicolas NinUnidad de Cuidados Intensivos, Hospital Español Dr. "Juan J. Crottoggini", Administración de los Servicios de Salud del Estado (ASSE), Montevideo, Uruguay.
F Javier HurtadoUnidad de Cuidados Intensivos, Hospital Español Dr. "Juan J. Crottoggini", Administración de los Servicios de Salud del Estado (ASSE), Montevideo, Uruguay.
Juan Pablo TosarLaboratorio de Genómica Funcional, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Carlos RobelloLaboratorio de Interacciones Hospedero-Patógeno, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Gonzalo GreifLaboratorio de Interacciones Hospedero-Patógeno, Institut Pasteur de Montevideo, Montevideo, Uruguay.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) remains a leading cause of infectious disease-related mortality. Annually, 10 million people contract TB, resulting in 1.5 million deaths, despite being a preventable and curable disease. Severe TB cases necessitate Intensive Care Unit (ICU) admission, with mortality rates ranging from 15.5 to 65.9%. Recent research highlights the role of microRNAs (miRNAs) in infectious disease diagnosis, with studies reporting distinct miRNA profiles in active pulmonary TB and sputum samples. This study aims to identify miRNAs as potential prognostic biomarkers for severe TB in ICU patients. Total RNA was extracted from the serum of ICU TB patients and controls. miRNA libraries were prepared and high throughput sequenced using a MiSeq Illumina platform. Differential miRNA abundance between patients and controls was analyzed with sRNAtoolbox, and DESeq2 was used for comparisons. Results demonstrated three differentially abundant miRNAs in severe TB patients' serum, validated by RT-qPCR. Stratifying patients by outcome revealed a significant difference in the ratio between two miRNAs: hsa-miR-378a-3p and hsa-miR-423-5p. The analysis showed that a miRNA-423-5p/miRNA-378a-3p ratio < 27 is associated with a poor prognosis, highlighting its potential as a prognostic indicator of disease severity. These findings are promising and warrant validation, while assessing these biomarkers in non-severe TB settings could further help identify more aggressive forms of the disease. In conclusion, this study explores the potential of circulating miRNAs as prognostic tools for severe TB cases in the ICU, offering a promising avenue for improving clinical decision-making and patient outcomes. Further validation and exploration in diverse TB contexts are essential for comprehensive understanding and application.

Indexed as

critical care medicinemiRNAMycobacterium tuberculosissmall RNAtuberculosis

Identifiers

PMID42638751
PMCPMC13494986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.